Finnhub•2026-04-16
IRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026IRTC — iRhythm Holdings, Inc
NASDAQ · Health Care · Health Care
$118.88-29.66%Market cap3.77B
- Latest Close
- $118.88
- 30-Day Move
- -29.7%
- Market Cap
- $3.8B
- Shares Outstanding
- 32,320,000
- P/B Ratio
- 37.43
- ROE
- -29.2%
Analyst consensus: Buy · 21 analysts
NASDAQ:IRTCHealth Care / Health CareDelayed public snapshot
iRhythm Holdings, Inc
A read-only Alphactor snapshot foriRhythm Holdings, Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$118.88
30-Day Move
-29.7%
Market Cap
$3.8B
Shares Outstanding
32,320,000
P/B Ratio
37.43
ROE
-29.2%
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$118.88
-29.7%last 90 delayed daily bars
Market cap$3.8B
90D High
$191.40
90D Low
$112.31
Avg Volume
600,527
What stands out
Gross margin is running at 70.6%, which gives a quick read on operating quality before you open the full model.
Net margin is -6.0%, useful for comparing IRTC against peers in Health Care.
IRTC is down 29.7% over the last 30 trading days shown on this page.
Latest operating income is $-50M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$57.84
Rule of 40
30.9%
Dark Pool Short %
43.4%
Fundamentals snapshot
Latest Close
$118.88
30-Day Move
-29.7%
Market Cap
$3.8B
Shares Outstanding
32,320,000
P/B Ratio
37.43
ROE
-29.2%
ROA
-4.4%
Gross Margin
70.6%
Operating Margin
-7.7%
Net Margin
-6.0%
Debt / Equity
4.25
Current Ratio
4.63
Latest Revenue
$747M
Financial statement snapshot
Revenue
$747M
Gross Profit
$527M
Operating Income
$-50M
Net Income
$-45M
Gross Margin
7057.0%
Net Margin
-596.0%
Current Ratio
4.63
Debt / Equity
4.25
Valuation snapshot
Fair Value
$57.84
Upside / Downside
-51.3%
Signal
Overvalued
Implied Growth
33.4%
DCF
$15.43
EV/Rev
$100.26
Growth Assumption
22.1%
Discount Rate
9.9%
Terminal Growth
2.0%
Base FCF
$35M
Valuation spread
Current Price
$118.88
Composite Fair Value
$57.84
DCF
$15.43
EV/Rev
$100.26
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Quality snapshot
Altman Z
2.73
Grey
Piotroski
6
Moderate (4-6)
Cash Conversion
-1.82x
Rule of 40
30.9%
Acceptable
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $411M | $-87M | $-116M | $-53M |
| 2023-12-31 | $493M | $-114M | $-123M | $-91M |
| 2024-12-31 | $592M | $-115M | $-113M | $-46M |
| 2025-12-31 | $747M | $-50M | $-45M | $35M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Benzinga•2026-04-15
Truist Securities Maintains Buy on iRhythm Holdings, Lowers Price Target to $170After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$30M
Buys
0
Sells
69
Buy Value
$0
Sell Value
$30M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-16 | Smith Mervin | Sell | 2,585 | $114.30 |
| 2026-03-12 | Patten Jason H | A | 2,218 | $0.00 |
| 2026-03-02 | Smith Mervin | Sell | 600 | $128.44 |
| 2026-03-02 | Smith Mervin | Sell | 752 | $128.44 |
| 2026-03-02 | Turakhia Minang | Sell | 1,230 | $128.45 |
| 2026-03-02 | Turakhia Minang | Sell | 1,310 | $128.45 |
| 2026-03-02 | Turakhia Minang | Sell | 1,487 | $128.44 |
| 2026-03-02 | Rosenbaum Marc Wade | Sell | 417 | $128.45 |
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-05-15
--
--
Vanguard Group
Filed 2026-01-29
$587M
+2.2%
BlackRock
Filed 2024-05-10
$283M
--
Capital Research Global Investors
Filed 2025-08-13
$232M
--
Geode Capital Management
Filed 2026-02-09
$152M
+8.6%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.33
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
21
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.